Historical review from 2026-11-14. Current price and availability are unconfirmed; check the original marketplace.
Hydrofy demonstrates strong unit economics with 85% profit margins and an attractive 2.01x annual profit multiple, well below typical SaaS benchmarks. Verified financials and $203/mo net profit provide concrete traction in a specialized niche (hydroponic gardening). However, the modest $238/mo revenue base and absence of disclosed user count, churn metrics, and customer acquisition details create material uncertainty around durability and defensibility. The platform verification is a significant strength, but a buyer should confirm retention, competitive positioning, and whether this revenue is derived from subscription, in-app purchase, or one-time sales before committing capital.
While the verified $203/mo profit and 85% margins are genuine traction, the absolute revenue base ($238/mo) is modest and the absence of disclosed user count, retention curves, organic growth data, or customer list makes it difficult to value the business assets being purchased. A solo founder could rebuild a functional iOS hydroponic logging app with AI-assisted diagnosis using SwiftUI, a managed backend (Firebase or Supabase), and AI APIs (OpenAI Vision for plant diagnosis) in 8 weeks for $2.5–6K. The primary acquisition value—paying user base, retention cohorts, and organic distribution channels—remains unverified. At $4,900, the buyer is paying 24x monthly profit, betting that undisclosed customer quality, retention, and growth justify the premium over building in-house with known traction trajectories.
Cash estimate includes the AI tools, APIs and infrastructure needed for a solo founder to recreate the software. Build time is informational and lightly weighted. The verdict is driven mainly by customers, users, verified earnings, retention, distribution, brand, data and operating history.
Hydrofy helps home hydroponic growers plan gardens, log pH and nutrient readings, track plants from seed to harvest, and spot problems with AI-assisted diagnosis on iPhone and iPad.
Opens the original listing on TrustMRR
Get new listings with asking prices, monthly profit, deal scores, and key risks.
The best reviewed deals, concise and evidence-first. Unsubscribe anytime.
Preliminary screening based on marketplace and public data. Verify all financial, legal, technical, customer, and operational claims independently before making an acquisition decision. This is not financial or legal advice.